http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Celcuity To Present at Upcoming Needham and Stifel Investor Conferences
-
Celcuity Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
-
Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2024 Financial Results and Webcast/Conference Call
-
Celcuity to Participate at Upcoming Cowen and Leerink Investor Conferences
-
Celcuity (CELC) Presents Overall Survival Data from Phase 1b Study Evaluating Gedatolisib in Combination with Palbociclib and Endocrine Therapy
-
Celcuity Presents Overall Survival Data from Phase 1b Study Evaluating Gedatolisib in Combination with Palbociclib and Endocrine Therapy at the 2024 San Antonio Breast Cancer Symposium
-
Celcuity Inc. Reports Third Quarter Financial Results and Provides Corporate Update
-
Celcuity Inc. To Present at Upcoming Stifel and Jefferies Investor Conferences
-
Celcuity Inc. Schedules Release of Third Quarter 2024 Financial Results and Webcast/Conference Call
-
Celcuity Inc. Reports Second Quarter Financial Results and Provides Corporate Update
-
Celcuity Inc. Schedules Release of Second Quarter 2024 Financial Results and Webcast/Conference Call
-
Celcuity To Participate in Jefferies Global Healthcare Conference
-
Celcuity (CELC) Announces Plan to Initiate a Phase 3 Clinical Trial for Gedatolisib as First-Line Treatment for HR+/HER2- Advanced Breast Cancer and Secures Approximately $62 Million Debt Financing
-
Celcuity Inc. Announces Plan to Initiate a Phase 3 Clinical Trial for Gedatolisib as First-Line Treatment for HR+/HER2- Advanced Breast Cancer and Secures Approximately $62 Million Debt Financing
-
Celcuity Inc. Reports First Quarter Financial Results and Provides Corporate Update
-
Celcuity Inc. Schedules Release of First Quarter 2024 Financial Results and Webcast/Conference Call
-
Celcuity To Present at Upcoming Needham and Stifel Investor Conferences
-
Celcuity Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
-
Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2023 Financial Results and Webcast/Conference Call
-
Celcuity to Participate in Leerink Partners Global Biopharma Conference 2024
-
Celcuity to Participate in Cowen’s 44th Annual Health Care Conference
-
Celcuity Announces First Patient Dosed in Phase 1b/2 CELC-G-201 Clinical Trial of Gedatolisib for the Treatment of Metastatic Castration Resistant Prostate Cancer
-
Celcuity (CELC) Appoints Eldon Mayer as Chief Commercial Officer
-
Celcuity Appoints Eldon Mayer as Chief Commercial Officer
-
Celcuity Presents Preclinical Data on Therapeutic Effects of Gedatolisib in Breast Cancer Models at the 2023 San Antonio Breast Cancer Symposium
-
Celcuity to Present Preclinical Data for Gedatolisib at the 2023 San Antonio Breast Cancer Symposium
-
Celcuity to Participate in the 6th Annual Evercore ISI HealthCONx Conference
-
Celcuity Inc. Reports Third Quarter 2023 Financial Results and Provides Corporate Updates
-
Celcuity Inc. Schedules Release of Third Quarter 2023 Financial Results and Webcast/Conference Call
-
Celcuity To Present at Upcoming Stifel and Jefferies Investor Conferences
-
Celcuity to Host Virtual Science Day for Investors
-
Celcuity (CELC) Enters a Clinical Trial Collaboration and Supply Agreement with Bayer to Provide Nubeqa
-
Celcuity Enters into a Clinical Trial Collaboration and Supply Agreement with Bayer to Provide Nubeqa® (darolutamide) for Planned Phase 1b/2 Clinical Trial
-
Celcuity Announces Plan to Conduct Phase 1b/2 Clinical Trial in Metastatic Castration Resistant Prostate Cancer
-
Celcuity Inc. Reports Second Quarter 2023 Financial Results and Provides Corporate Updates
-
Celcuity Inc. Schedules Release of Second Quarter 2023 Financial Results and Webcast/Conference Call
-
Celcuity to Participate in the BTIG Virtual Biotechnology Conference 2023
-
Celcuity (CELC) to Join Russell 2000 and 3000 Indexes
-
Celcuity Set to Join Russell 2000 and 3000 Indexes
-
Celcuity to Participate in Upcoming Craig-Hallum and Jefferies Investor Conferences
-
Celcuity Inc. Reports First Quarter 2023 Financial Results and Provides Corporate Updates
-
Celcuity (CELC) Presents Updated Results from Phase 1b Study of Gedatolisib
-
Celcuity Presents Updated Results from Phase 1b Study of Gedatolisib in Treatment-Naïve Patients at the 2023 ESMO Breast Cancer Annual Congress
-
Celcuity Inc. Schedules Release of First Quarter 2023 Financial Results and Webcast/Conference Call
-
Celcuity to Present Updated Results for Treatment-Naïve Patients from Phase 1b Study of Gedatolisib at the 2023 ESMO Breast Cancer Annual Congress
-
Celcuity (CELC) Presents Preclinical Data on Therapeutic Effects of Gedatolisib
-
Celcuity Presents Preclinical Data on Therapeutic Effects of Gedatolisib in Gynecological Cancer Models at AACR Annual Meeting 2023
-
Celcuity to Participate in 22nd Annual Needham Virtual Healthcare Conference
-
Celcuity Inc. Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
-
Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2022 Financial Results and Webcast/Conference Call

